GET DAILY SIGNALSAlphatec Holdings (ATEC) Reports +13% Revenue Growth in Q3 but Lowers Full-Year Outlook
Key Takeaways
- Alphatec Holdings (ATEC) reported total revenue of $221 million for the third quarter of 2026, up 13% year over year but below the consensus estimate of roughly $225 million.
- Surgical revenue rose 14% to $202 million, supported by approximately 20% case volume growth and a 25% increase in net new surgeon users.
- GAAP (Generally Accepted Accounting Principles) net loss narrowed to $5 million, or $0.03 per share, from a $28.6 million loss, or $0.19 per share, a year earlier.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $38 million, or 17.3% of revenue, expanding 400 basis points year over year.
- Management lowered its full-year 2026 total revenue outlook to approximately $862 million and generated $6 million in free cash flow during the quarter.
- For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages covering Alphatec Holdings in detail.
- Explore Trending AI Robots to see AI-driven trading strategies currently drawing attention across the market.
Why These Results Matter
Alphatec Holdings (ATEC) is a spine-focused medical device company that has built its growth around procedure volume and surgeon adoption in a competitive orthopedic space. As the firm works toward consistent GAAP profitability, metrics like margin expansion, free cash flow, and revenue trends remain key watchpoints. This quarter stands out because any softness in product mix can affect both top-line results and the longer-term path to profitability. The updated full-year outlook also gives a useful signal on whether the underlying growth story holds steady into the final months of 2026.
What the Numbers Show
Alphatec Holdings (ATEC) posted total revenue of $221 million for the quarter ended September 30, 2026. That represents a 13% increase from $196.5 million a year earlier, though it fell short of the consensus estimate near $225 million. The gap stemmed mainly from lower biologics attachment, which management noted and is working to improve. Surgical revenue advanced 14% to $202 million, while surgical hardware revenue rose 17%.
On the bottom line, the GAAP net loss narrowed to $5 million, or $0.03 per share, compared with a $28.6 million loss, or $0.19 per share, in the same quarter last year. Non-GAAP net income came in at $15 million. Adjusted EBITDA climbed to $38 million, or 17.3% of revenue, which is 400 basis points higher year over year. GAAP gross margin stood at 71.5%, and the company produced $6 million in free cash flow.
For the full year 2026, management now projects total revenue of approximately $862 million, a reduction from its previous target. This includes roughly $789 million in surgical revenue and $73 million from EOS. Adjusted EBITDA is expected near $137 million, with free cash flow around $10 million.
Market Reaction and Sentiment
The third-quarter results sent a mixed signal. Strong underlying demand in surgery showed through in double-digit gains for hardware revenue, case volumes, and new surgeon additions, which supports the core growth thesis. At the same time, the revenue shortfall linked to biologics and the lowered full-year guidance introduced some near-term uncertainty around execution. Shares had already been trading well below their 52-week high ahead of the report, and analyst views remained generally constructive but measured. The post-earnings response appears to reflect investors balancing durable procedural momentum against the biologics weakness and revised outlook.
What to Watch Going Forward
Investors will now focus on management’s ability to lift biologics attachment rates, the main factor behind the revenue miss. Progress here could help align strong surgical demand with overall revenue growth. Margin trends and cash generation also deserve attention, given the 400-basis-point expansion in Adjusted EBITDA margin and the positive free cash flow this quarter. Maintaining that leverage while funding product development and surgeon recruitment will be important in upcoming periods.
Adoption of newer platforms and technologies should also be monitored, as these are positioned as competitive advantages in the spine market. Case volume growth and net new surgeon additions provide a direct read on demand strength. Finally, commentary around fourth-quarter trends and any updates on industry factors such as hospital spending and reimbursement will help frame expectations.
Using Tickeron Tools in My Analysis
When reviewing results like these, I often run a quick scan with Tickeron’s AI Screener to compare Alphatec Holdings (ATEC) against peers on fundamentals and technical signals. It helps surface context on how the name stacks up within the broader medical device group without spending hours on manual filtering.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ATEC in downward trend: price may drop because broke its higher Bollinger Band on October 22, 2026
ATEC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 45 similar instances where the stock broke above the upper band. In 38 of the 45 cases the stock fell afterwards. This puts the odds of success at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 57 cases where ATEC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ATEC as a result. In 75 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ATEC just turned positive on October 22, 2026. Looking at past instances where ATEC's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Following a +8.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATEC advanced for three days, in 266 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 194 of 253 cases where ATEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ATEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (-145.506) is very low in comparison to the industry average of (3.870). P/E Ratio (-16.014) is within average values for comparable stocks, (1.382). ATEC's Projected Growth (PEG Ratio) (91.200) is very high in comparison to the industry average of (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.980) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company with interests in medical equipment and supplies
Industry MedicalNursingServices
Advertisement